<DOC>
	<DOCNO>NCT02412228</DOCNO>
	<brief_summary>The goal proposal develop effective well tolerate regimen . Ixazomib appear great activity bortezomib less peripheral neuropathy .</brief_summary>
	<brief_title>BrUOG 299 : Ixazomib , Oral Metronomic Cyclophosphamide Dexamethasone First-Line Treatment Multiple Myeloma : A Phase II Brown University Oncology Group Study .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Age ≥ 18 year age Histologically confirm multiple myeloma accord WHO classification . Pathology report send BrUOG confirmation Diagnosis Multiple Myeloma previously treat ( although patient receive emergent steroid and/or local radiation therapy permit enter study ) . , Details need submit BrUOG date dos . Measureable disease define either elevate serum Mprotein , urine Mprotein , bone marrow involvement &gt; 30 % serum free light chain per IMWG criterion . Confirmation send BrUOG , see section 7 criterion Life expectancy ≥ 6 month , confirmation per treat investigator require Absolute neutrophil count ( ANC ) ≥ 1,000/mm3 platelet count ≥ 75,000/mm3 . Platelet transfusion help patient meet eligibility criterion allow within 3 day study enrollment . If transfusional support provide , please document submission BrUOG Calculated creatinine clearance ≥30 mL/min ( base CockcroftGault Equation ) For male : Creatinine Clearance = ( 140age [ year ] x weight [ kg ] ) 72 x ( serum creatinine [ mg/dL ] ) For female : Creatinine Clearance = 0.85 ( 140age [ year ] x weight [ kg ] ) 72 x ( serum creatinine [ mg/dL ] ) ECOG performance status 01 . Adequate Liver function ; AST ALT &lt; 3.0 x upper limit normal ( ULN ) ; Total bilirubin &lt; 1.5x ULN Voluntary write consent must give performance study relate procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing informed consent form 90 day last dose study drug obtain pregnancy test , must come back negative prior drug , OR Agree practice true abstinence line prefer usual lifestyle subject obtain serum pregnancy test , must come back negative prior drug . ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Documentation confirmation conversation patient commitment contraception require note sent BrUOG . Female 's menopausal status document submit BrUOG applicable . Pregnancy test , applicable , required send BrUOG . Male patient , even surgically sterilize ( ie , status postvasectomy ) , must agree one following : Agree practice effective barrier contraception entire study treatment period 90 day last dose study drug , OR Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Documentation confirmation conversation patient commitment contraception require note sent BrUOG . Female patient lactate positive serum pregnancy test screening period . Any surgery within 14 day enrollment . Radiotherapy within 14 day enrollment . Central nervous system involvement ( myelomarelated ) . Active infection require systemic antibiotic therapy serious active infection within 7 day study enrollment . Evidence current uncontrolled cardiovascular condition , include uncontrolled hypertension , uncontrolled cardiac arrhythmia , symptomatic congestive heart failure , unstable angina , myocardial infarction within past 6 month . Systemic treatment , within 14 day first dose ixazomib , strong inhibitor CYP1A2 ( fluvoxamine , enoxacin , ciprofloxacin ) , strong inhibitor CYP3A ( clarithromycin , telithromycin , itraconazole , voriconazole , ketoconazole , nefazodone , posaconazole ) strong CYP3A inducer ( rifampin , rifapentine , rifabutin , carbamazepine , phenytoin , phenobarbital ) , use Ginkgo biloba St. John 's wort . Ongoing active systemic infection , active hepatitis B C virus infection , know human immunodeficiency virus ( HIV ) positive . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . If applicable , investigator document applicable Known allergy study medication , analogue , excipients various formulation agent . If applicable , investigator document applicable Known GI disease GI procedure could interfere oral absorption tolerance ixazomib include difficulty swallowing . If applicable , investigator document applicable Diagnosed treat another malignancy within 2 year study enrollment previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection . Patient ≥ Grade 2 peripheral neuropathy Grade 1 pain . Participation therapeutic clinical trial , include investigational agent include trial , within 30 day start trial throughout duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>